Patel A MD; Khalsa B BS; Lord B DO; Sandrasegaran K MD; Lall C MD.
Medical Imaging—Radiation Oncology—Pictorial Essay
Planting the seeds of success: CT-guided gold seed fiducial marker placement to guide robotic radiosurgery
Version of Record online: 21 SEP 2012
© 2012 The Authors. Journal of Medical Imaging and Radiation Oncology © 2012 The Royal Australian and New Zealand College of Radiologists
Journal of Medical Imaging and Radiation Oncology
Volume 57, Issue 2, pages 207–211, April 2013
How to Cite
Patel, A., Khalsa, B., Lord, B., Sandrasegaran, K. and Lall, C. (2013), Planting the seeds of success: CT-guided gold seed fiducial marker placement to guide robotic radiosurgery. Journal of Medical Imaging and Radiation Oncology, 57: 207–211. doi: 10.1111/j.1754-9485.2012.02445.x
Disclosures/Conflicts of Interest:
K Sandrasegaran has received educational grants from Siemens Medical Solutions, Erlangen, Germany; and Bayer Health Care, Wayne, NJ, USA. All other authors have nothing to disclose.
Indiana University School of Medicine, Department of Radiology and Imaging Sciences is a CT Beta test site for Philips Healthcare.
- Issue online: 2 APR 2013
- Version of Record online: 21 SEP 2012
- Manuscript Accepted: 10 MAY 2012
- Manuscript Received: 22 OCT 2011
- extracranial radiosurgery;
- fiducial markers;
- interventional radiology;
- radiation oncology;
- stereotactic body radiation therapy
Fiducial marker (FM)-guided stereotactic body radiation therapy (SBRT) allows for precise targeting and delivery of radiation to a tumor site. In this article, we briefly discuss SBRT, provide examples to describe CT-guided FM placement to guide SBRT, and discuss some of the associated risks and benefits. This article serves as a pictorial review for body imagers and interventional radiologists who perform CT-guided procedures and interpret diagnostic studies for oncology patients. CT-guided FMs were placed in patients who were appropriate candidates for SBRT. One week following placement, patients underwent diagnostic CT and/or MR examinations in order to include the FM data in the development of a treatment plan. From October 2007–November 2009, a total of 89 patients were implanted with FMs. Sites of implantation included lung, liver, bone, chest and abdominal wall, and peritoneum/retroperitoneum. Complications included pneumothorax and FM migration. Twenty-one patients (33%) with lung FM placement experienced at least a small pneumothorax and 6 patients (9%) required thoracostomy tubes. FM migration occurred in 5 patients (8%) with lung placement. SBRT provides a safer and more effective alternative to conventional radiotherapy, and CT-guided FM implantation of tumor sites increases the precision of SBRT. Technical improvements in FM placement can limit the complications associated with the procedure and further enable highly localized tumor therapy.